Senti Biosciences (SNTI) Stock: Buy, Sell, or Hold?
SNTI - Senti Biosciences, Inc. Common Stock
$0.23
0.00 (0.84%)
β²
5d:
-28.81%
30d:
-29.12%
90d:
-50.74%
WAIT
LOW Confidence
Analysis Updated: Oct 16, 2026 12:00 AM ET
Earnings: Nov 12, 2026
23d
Get Alerted When SNTI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
βΈοΈ WAIT FOR STABILIZATION: SNTI is down 28.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
βΈοΈ WAIT FOR STABILIZATION: SNTI is down 28.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: SNTI is currently trading at $0.23, which is considered oversold relative to its 30-day fair value range of $0.28 to $0.34.
Technical Outlook: Technically, SNTI is in a strong downtrend. Immediate support is located at $0.21, while resistance sits at $0.35.
Market Sentiment: SNTI scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $13.50 (+5902.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SNTI is in a strong downtrend. Immediate support is located at $0.21, while resistance sits at $0.35.
Market Sentiment: SNTI scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $13.50 (+5902.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.28 -
$0.34
Company Quality Score
38/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 5902.7% below Wall St target ($13.50)
- WARNING: Composite score 38/100 in the bottom quintile β this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.28 -
$0.34
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.21
Resistance Level
$0.35
Current Trend
Strong Downtrend
Technical data as of
Oct 19, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.24
Wall Street Target
$13.50
(+5902.7%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: October 19, 2026 4:24 PM ET
Data refreshes hourly during market hours. Next update: 5:24 PM
Data refreshes hourly during market hours. Next update: 5:24 PM
π₯ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SNTI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
22 analysts |
$295 | 52 HOLD |
|
REGN
Regeneron Pharmaceutical⦠|
BUY
28 analysts |
$864 | 41 HOLD |
|
PRAX
Praxis Precision Medicin⦠|
STRONG BUY
20 analysts |
$650 | 57 HOLD |
|
DYN
Dyne TherapeuticsΒ Inc |
STRONG BUY
17 analysts |
$36 | 61 BUY |
|
ACAD
ACADIA Pharmaceuticals I⦠|
STRONG BUY
20 analysts |
$31 | 60 BUY |